ProCE Banner Activity

Future Treatment Strategies for Acute Myeloid Leukemia—Emerging Targeted Therapy Combinations and Beyond

Podcast Episodes

Listen to Naval G. Daver, MD, discuss his thoughts on the most promising investigational agents and treatment strategies currently in clinical trials for the treatment of patients with acute myeloid leukemia (AML).

Released: August 14, 2020

Expiration: August 13, 2021

No longer available for credit.

Share

Faculty

Naval G. Daver

Naval G. Daver, MD

Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Naval G. Daver, MD

Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Naval G. Daver, MD, has disclosed that he has received consulting fees from AbbVie, Agios, Astellas, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, ImmunoGen, Incyte, Jazz, Karyopharm, Novartis, Otsuka, Pfizer, and Sunesis and funds for research support from AbbVie, Astellas, Bristol-Myers Squibb, Daiichi Sankyo, Forty-Seven, Genentech, Glycomimetics, Hanmi, ImmunoGen, Incyte, Karyopharm, Newave, NOHLA, Novartis, Pfizer, Servier, Sobi, Sunesis, and Trovagene.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason Everly, PharmD, BOCP, CHCP, has no relevant conflicts of interest to report.

Terrence Fagan,

Associate Scientific Director

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin L. Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.